Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$26.85 USD
+0.71 (2.72%)
Updated Oct 15, 2025 04:00 PM ET
After-Market: $26.86 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TVTX 26.85 +0.71(2.72%)
Will TVTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
What Makes Travere (TVTX) a New Strong Buy Stock
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Other News for TVTX
Is TVTX consolidating before a move? NR7 shows up after dropping 0.23%
180 Bullish Setup appears for TVTX after 4.13% move
Is TVTX consolidating before a move? NR7 shows up after sinking 3.49%
TVTX forms Shooting Star Candlestick on October 9
TVTX forms 180 Bullish Setup on October 8